<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204230</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT00204230</nct_id>
  </id_info>
  <brief_title>MMF and Calcineurin Inhibitor Withdrawal in CAN</brief_title>
  <official_title>Randomized Controlled Study: Effect of Mycophenolatmofetil in Patients With Histologically Proven Chronic Allograft Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <brief_summary>
    <textblock>
      Prospective, randomised study: Effect of mycophenolatmofetil (MMF) and CNI withdrawal in&#xD;
      patients with histologically proven chronic allograft nephropathy Indication: change in&#xD;
      immunosuppressive treatment of chronic allograft nephropathy (CAN)after renal transplantation&#xD;
      Hypothesis: Antimetabolite MMF is able to stop progression of CAN and improve blood pressure/&#xD;
      metabolic parameters and structural vessel wall changes&#xD;
&#xD;
      Primary Target:effects of CNI withdrawal and MMF on renal function: stabilisation and/or&#xD;
      improvement Secondary Targets: Incidence of adverse events Evaluation of the calcineurin&#xD;
      inhibitor free MMF treatment effects on blood pressure, lipids, glucose metabolism and on&#xD;
      structural and functional vesselwallchanges Method:open prospective, randomized two-tailed,&#xD;
      monocentric study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomised study: Effect of mycophenolatmofetil in patients with histologically&#xD;
      proven chronic allograft nephropathy&#xD;
&#xD;
      SYNOPSIS&#xD;
&#xD;
      Indication: change in treatment to improve the course of chronic allograft nephropathy&#xD;
&#xD;
      Method: open prospective, randomized two-tailed, non blinded monocentric study&#xD;
&#xD;
      Follow up period: 35 Weeks&#xD;
&#xD;
      Number of patients: 2 x 86 patients&#xD;
&#xD;
      Inclusion criteria: • Written informed consent&#xD;
&#xD;
        -  Reduction of graft function: Increase of serum creatinine &gt;/= 0,1mg/dl/month in the&#xD;
           previous 6 months before start of the study and/or new occurrence or increasing&#xD;
           proteinuria in the last 6 months before start of the study&#xD;
&#xD;
        -  Serum creatinine &lt; 4 mg/dl&#xD;
&#xD;
        -  Biopsy within the last 3 months&#xD;
&#xD;
        -  histologically proved chronic allograft nephropathy (graft glomerulopathy, chronic&#xD;
           rejection ,interstitial fibrosis, tubular atrophy, vascular arteriosclerosis,hyalinosis)&#xD;
&#xD;
        -  &gt;1 year after renal allografting&#xD;
&#xD;
        -  At least 5 mg/day of prednisolone or equivalent dose&#xD;
&#xD;
      Exclusion criteria: • Malignomas&#xD;
&#xD;
        -  Gravidity or Lactation&#xD;
&#xD;
        -  Participation in other studies&#xD;
&#xD;
        -  Severe infections&#xD;
&#xD;
        -  Florid gastrointestinal Ulcer&#xD;
&#xD;
        -  Age between 18 and 70 years&#xD;
&#xD;
        -  Leukopenia with less that 3000/l leucocytes, Anaemia Hb  9 g/dl&#xD;
&#xD;
        -  Therapy with mycophenolatmofetil in the past 6 months&#xD;
&#xD;
        -  Acute rejections in the apst 6 months&#xD;
&#xD;
      Study protocol:&#xD;
&#xD;
      Phase I: Week 1.-3. Conversion to Triple-Drug-Therapy, consisting of Mycophenolatmofetil,&#xD;
      corticosteroids (e.g. prednisolone) and ciclosporine A or Tacrolimus&#xD;
&#xD;
      1. Addition of Mycophenolatmofetil (MMF) to the previous immosuppressive treatment,&#xD;
      consisting of ciclosporine A (CsA) or Tacrolimus (FK506) in combination with corticosteroids,&#xD;
      e.g. prednisolone (P). In the case that azathioprine (AZA) had been given, AZA is replaced by&#xD;
      MMF. The therapy with MMF starts 3 days after the elimination of azathioprine.&#xD;
&#xD;
      The addition of MMF follows the following scheme if nothing else is indicated:&#xD;
&#xD;
        1. week: 1g/day, 2.week: 1,5g/day, 3.week: 2g/day&#xD;
&#xD;
        2. Ciclosporine A bzw. tacrolimus: Target whole trough blood levels:&#xD;
&#xD;
           CsA: 80-120 ng/ml (HPLC) FK506: 4-7 ng/ml (IMX Tacrolimus, Abbott)&#xD;
&#xD;
        3. Corticosteroids, e.g. prednisolone: The previous dosage is continued, but at least 5 mg&#xD;
           prednisolone/day (or equivalent) must be given&#xD;
&#xD;
      Phase II: week 4.-9.&#xD;
&#xD;
      Randomisation at the beginning of week 4:&#xD;
&#xD;
      All patients receiving at least 3 x 500 mg MMF per day were randomised as follows Group A:&#xD;
      Continuation of the triple therapy Group B: Elimination of CsA bzw. FK506 The ciclosporine A-&#xD;
      or tacrolimus-dosage is reduced ba 33% each 2 weeks so that after 6-8 weeks a total&#xD;
      elimination of the drugs is reached.&#xD;
&#xD;
      Phase III: week 10.-35.&#xD;
&#xD;
      Continuous therapy with...:&#xD;
&#xD;
      Group A: Triple therapy MMF / CsA bzw. FK506 / Corticosteroids e.g. Prednisolone Group B:&#xD;
      Dual therapy MMF / Corticosteroids e.g. Prednisolone&#xD;
&#xD;
      Primary Endpoint:&#xD;
&#xD;
      Comparison of the development of 1/creatinine in both branches 32 weeks after randomization&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
        -  Occurrence of...&#xD;
&#xD;
             -  acute rejections&#xD;
&#xD;
             -  infections&#xD;
&#xD;
             -  malignomas&#xD;
&#xD;
             -  gastrointestinal disorders&#xD;
&#xD;
        -  Blood pressure evolution and number of antihypertensive drugs&#xD;
&#xD;
        -  Changes concerning the lipid state&#xD;
&#xD;
        -  Changes concerning the glucose metabolism&#xD;
&#xD;
        -  Changes in metabolism of uric acid&#xD;
&#xD;
        -  Comparison of the development of 1/creatinine within each branch 6 months before and 6&#xD;
           months after therapy conversion&#xD;
&#xD;
        -  Comparison of drop out rate in branches A und B&#xD;
&#xD;
        -  Pharmacokinetics of mycophenolic acid (MPA) based on a new method of abbreviated area&#xD;
           under the curve (AUC) determination&#xD;
&#xD;
        -  vessel wall changes of the carotid arteries measured by high resolultion ultrasound&#xD;
           methods and hemodynamic parameters measured by task force equipment before and 9 month&#xD;
           after cni withdrawal and MMF addition&#xD;
&#xD;
      Criteria for study discontinuation:&#xD;
&#xD;
        -  Sepsis&#xD;
&#xD;
        -  Occurrence of acute rejections&#xD;
&#xD;
        -  Graft loss&#xD;
&#xD;
        -  Other severe adverse events&#xD;
&#xD;
        -  patients decision&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 1999</start_date>
  <completion_date>September 2002</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>course of renal function over 35 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>after 35 weeks of follow up:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-acute rejections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-infections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-malignomas</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-gastrointestinal disorders</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>development of blood pressure over 35 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of antihypertensive drugs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid state at entry and after 35 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose ,HBA1c at entry and after 35 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>uric acid at entry and after 35 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the development of 1/creatinine within each group at entry and 35 weeks after therapy conversion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve (AUC) determination of mycophenolic acid (MPA)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vessel wall changes of the carotid arteries IMD , compliance, distensibility and hemodynamic parameters CO, CI, at entry and after after cni withdrawal and MMF addition</measure>
  </secondary_outcome>
  <enrollment>86</enrollment>
  <condition>Immunosuppressive Agents</condition>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Written informed consent Reduction of graft function: Increase of serum creatinine &gt;=&#xD;
        0,1mg/dl/month in the previous 6 months before start of the study and/or new occurrence or&#xD;
        increasing proteinuria in the last 6 months before start of the study Serum creatinine &lt; 4&#xD;
        mg/dl Biopsy within the last 3 months histologically proved chronic allograft nephropathy&#xD;
        &gt;=1 year after renal allografting &gt;=5 mg/day Prednisolone or equivalent dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Malignomas Gravidity or Lactation Participation in other studies Severe infections&#xD;
        gastrointestinal Ulcer Age &lt;18 and &gt;70 years Leukopenia with less that 3000/dl leucocytes,&#xD;
        Anaemia Hb &gt; 9 g/dl Therapy with mycophenolatmofetil in the past 6 months Acute rejections&#xD;
        in the past 6 months&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara M Suwelack, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant. 2004 Apr;4(4):655-62.</citation>
    <PMID>15023160</PMID>
  </results_reference>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2005</last_update_posted>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Kidney Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

